6 results on '"Concepción Moll"'
Number of results to display per page
Search Results
2. Efficacy of Tocilizumab in Conventional Treatment-Refractory Adult-Onset Still's Disease: Multicenter Retrospective Open-Label Study of Thirty-Four Patients
- Author
-
Javier Rueda-Gotor, Alejandro Olivé, Inmaculada Ros Vilamajo, Ricardo Blanco, Jordi del Blanco, Vanesa Calvo-Río, José Llobet, Trinitario Pina, Mercedes Freire, M. Victoria Hernández, Sara Manrique Arija, Chamaida Plasencia-Rodríguez, Adela Gallego Flores, Santos Castañeda, Catalina Gómez Arango, Walter Alberto Sifuentes Giraldo, Carlos Marras, Miguel A. Caracuel, Miguel A. González-Gay, Francisco Ortiz-Sanjuán, M. Carmen González-Vela, María Luisa Velloso-Feijoó, C. Mata, Javier Narváez, Ana Urruticoechea, Concepción Moll-Tuduri, Esteban Rubio Romero, Javier Loricera, and Rosa Roselló
- Subjects
medicine.medical_specialty ,medicine.diagnostic_test ,business.industry ,Standard treatment ,Immunology ,Retrospective cohort study ,Surgery ,Discontinuation ,chemistry.chemical_compound ,Tocilizumab ,Rheumatology ,Refractory ,chemistry ,Prednisone ,Interquartile range ,Internal medicine ,Erythrocyte sedimentation rate ,medicine ,Immunology and Allergy ,business ,medicine.drug - Abstract
Objective Adult-onset Still's disease (AOSD) is frequently refractory to standard therapy. Tocilizumab (TCZ) has demonstrated efficacy in single cases and in small series of patients with AOSD. The aim of this multicenter study was to assess the efficacy of TCZ in patients with AOSD refractory to conventional treatment. Methods This was a retrospective open-label study of TCZ treatment in 34 patients with AOSD who had experienced an inadequate response to corticosteroids and at least 1 standard synthetic immunosuppressive drug and also, in many cases, biologic agents. Results The mean ± SD age of the patients (8 men and 26 women) was 38.7 ± 16.1 years. The median duration of AOSD before TCZ was initiated was 4.2 years (interquartile range [IQR] 1–9 years). The initial dosages of intravenous TCZ were 8 mg/kg every 4 weeks in 22 patients, 4 mg/kg every 4 weeks in 2 patients, and 8 mg/kg every 2 weeks in 10 patients. TCZ treatment resulted in rapid and maintained improvement in both clinical and laboratory parameters. After 1 year of TCZ therapy, the incidence of joint manifestations had decreased from 97.1% at baseline to 32.4%, the incidence of both cutaneous manifestations and fever had decreased from 58.8% to 5.9%, and the incidence of lymphadenopathy had decreased from 29.4% to 0%. A dramatic reduction in laboratory markers of inflammation, including the C-reactive protein level, the erythrocyte sedimentation rate, and the ferritin level, was achieved. The median dosage of prednisone was also reduced, from 13.8 mg/day (IQR 5–45) at the initiation of TCZ to 2.5 mg/day (IQR 0–30) at 12 months. After a median followup of 19 months (IQR 12–31 months), only 2 patients required permanent discontinuation of TCZ therapy because of severe infections. Conclusion TCZ treatment was associated with rapid and maintained clinical and laboratory improvement in patients with AOSD refractory to standard treatment. However, joint manifestations seem to be more refractory to treatment compared with systemic manifestations.
- Published
- 2014
3. RENACER study: Assessment of 12-month efficacy and safety of 168 certolizumab PEGol rheumatoid arthritis-treated patients from a Spanish multicenter national database
- Author
-
Jenaro Graña Gil, Hèctor Corominas, Felipe Joaquín Rivas Santirso, Desireé Ruiz Vilchez, Silvia Garcia-Diaz, María Pilar Navarro Alonso, Jesús Carlos Fernández, Anna Martínez-Cristóbal, Rosa Expósito Moliner, Juan Víctor Tovar Beltrán, José Raúl Noguera Pons, Antonio Gracia Pérez, José Ramón Lamua Riazuelo, Arantxa Conesa Mateos, Jaime Calvo Alén, Delia Taverner Torrent, Raúl Cortés Verdú, Rosa García Portales, Alejandro Muñoz Jiménez, Juan José Lerma Garrido, Concepción Moll Turudi, Angel Aragón Díez, Ana Urruticoechea Arana, José Miguel Ruiz Martín, María Jesús Martínez Blasco, Amalia Sánchez-Andrade Fernández, RENACER StudyGroup, Sergi Ordoñez Palau, Noemí Patricia Garrido Puñal, Vicenç Torrente-Segarra, Noelia Vázquez Fuentes, Manuel Fernandez Prada, Carlos Tomás Roura, José Antonio González Ferrández, Raúl Veiga Cabello, Pedro Giralt Celiméndiz, Asunción Acosta Pereira, Silvia Paredes González-Albo, [Torrente-Segarra, Vicenc] Hosp Gen Hospitalet St Joan Despi Moises Broggi, Dept Rheumatol, C Avinguda Josep Molins 29-41, Lhospitalet De Llobregat 08906, Catalunya, Spain, [Corominas, Hector] Hosp Gen Hospitalet St Joan Despi Moises Broggi, Dept Rheumatol, C Avinguda Josep Molins 29-41, Lhospitalet De Llobregat 08906, Catalunya, Spain, [Urruticoechea Arana, Ana] Hosp Can Misses, Dept Rheumatol, Ibiza, Spain, [Sanchez-Andrade Fernandez, Amalia] Complejo Hosp Univ Lucus Augusti, Dept Rheumatol, Lugo, Spain, [Tovar Beltran, Juan Victor] Hosp Gen Univ Elche, Dept Rheumatol, Elche, Spain, [Noguera Pons, Jose Raul] Hosp Gen Univ Elche, Dept Rheumatol, Elche, Spain, [Munoz Jimenez, Alejandro] Hosp Univ Virgen del Rocio, Dept Rheumatol, Seville, Spain, [Garrido Punal, Noemi Patricia] Hosp Univ Virgen del Rocio, Dept Rheumatol, Seville, Spain, [Martinez-Cristobal, Anna] Hosp Ribera, Dept Rheumatol, Alzira, Spain, [Gonzalez Ferrandez, Jose Antonio] Hosp Univ Guadalajara, Dept Rheumatol, Guadalajara, Spain, [Fernandez Prada, Manuel] Hosp Univ Ceuta, Dept Rheumatol, Ceuta, Spain, [Vazquez Fuentes, Noelia] Hosp Gen Hospitalet St Joan Despi Moises Broggi, Dept Rheumatol, St Joan Despi, Spain, [Garcia-Diaz, Silvia] Hosp Gen Hospitalet St Joan Despi Moises Broggi, Dept Rheumatol, St Joan Despi, Spain, [Acosta Pereira, Asuncion] Hosp Santa Creu & Sant Pau, Dept Rheumatol, Barcelona, Spain, [Ruiz Martin, Jose Miguel] Hosp Viladecans, Dept Rheumatol, Viladecans, Spain, [Lamua Riazuelo, Jose Ramon] Hosp Univ Henares, Dept Rheumatol, Alcala De Henares, Spain, [Exposito Moliner, Rosa] Hosp Comarcal Laredo, Dept Rheumatol, Laredo, Spain, [Ruiz Vilchez, Desiree] Hosp Univ Reina Sofia, Dept Rheumatol, Cordoba, Spain, [Veiga Cabello, Raul] Hosp Fuenlabrada, Dept Rheumatol, Fuenlabrada, Spain, [Carlos Fernandez, Jesus] Complejo Hosp Univ A Coruna, Dept Rheumatol, La Coruna, Spain, [Giralt Celimendiz, Pedro] Hosp St Bernabe, Dept Rheumatol, Berga, Spain, [Cortes Verdu, Raul] Hosp Publ LluisAlcanyis de Xativa, Dept Rheumatol, Valencia, Spain, [Aragon Diez, Angel] Hosp Univ Getafe, Dept Rheumatol, Getafe, Spain, [Tomas Roura, Carlos] Hosp Comarcal Mora dEbre, Dept Rheumatol, Mora Debre, Spain, [Moll Turudi, Concepcion] Hosp Gen MateuOrfila, Dept Rheumatol, Maho, Spain, [Taverner Torrent, Delia] Hosp Univ Reus, Dept Rheumatol, Reus, Spain, [Paredes Gonzalez-Albo, Silvia] Hosp Univ Reus, Dept Rheumatol, Reus, Spain, [Rivas Santirso, Felipe Joaquin] Clin Dr Rivas, Dept Rheumatol, Segovia, Spain, [Lerma Garrido, Juan Jose] Hosp Gen Castellon, Dept Rheumatol, Castellon De La Plana, Spain, [Garcia Portales, Rosa] Hosp Virgen de la Victoria Malaga, Dept Rheumatol, Malaga, Spain, [Ordonez Palau, Sergi] Hosp Arnau Vilanova, Dept Rheumatol, Lleida, Spain, [Gracia Perez, Antonio] Clin Quiron Valencia, Dept Rheumatol, Valencia, Spain, [Conesa Mateos, Arantxa] Hosp Clin Valencia, Dept Rheumatol, Valencia, Spain, [Calvo Alen, Jaime] Hosp Sierrallana, Dept Rheumatol, Torrelavega, Spain, [Grana Gil, Jenaro] EOXI CHU A Coruna, Dept Rheumatol, La Coruna, Spain, [Navarro Alonso, Maria Pilar] Hosp Fuenlabrada, Dept Rheumatol, Madrid, Spain, and [Martinez Blasco, Maria Jesus] Hosp Univ Mostoles, Dept Rheumatol, Mostoles, Spain
- Subjects
musculoskeletal diseases ,medicine.medical_specialty ,Survival rate ,Efficacy ,College-of-rheumatology ,Clinical practice ,Logistic regression ,03 medical and health sciences ,0302 clinical medicine ,Rheumatology ,Long-term ,Internal medicine ,medicine ,030212 general & internal medicine ,Certolizumab pegol ,Rheumatoid arthritis ,skin and connective tissue diseases ,Prospective cohort study ,030203 arthritis & rheumatology ,Gisea registry ,Clinical-practice ,Danish danbio registry ,business.industry ,Certolizumab PEGol ,Adalimumab ,Alpha agents ,medicine.disease ,Discontinuation ,Japanese patients ,Anti-tnf therapy ,Plus methotrexate ,Physical therapy ,National database ,Observational study ,Safety ,business ,medicine.drug ,Spanish population - Abstract
To assess effectiveness and safety of certolizumab PEGol (CZP) in rheumatoid arthritis (RA) patients after 12 months of treatment and to detect predictors of response.Observational longitudinal prospective study of RA patients from 35 sites in Spain. Variables (baseline, 3- and 12-month assessment): sociodemographics, previous Disease Modifying Anti-Rheumatic Drug (DMARD) and previous Biological Therapies (BT) use; TJC, SJC, ESR, CRP, DAS28, SDAI. Response variables: TJC, SJC, CRP, ESR, and steroids dose reductions, EULAR Moderate/Good Response, SDAI response and remission, DAS28 remission. Safety variables: discontinuation due to side-effects. Descriptive, comparative and Logistic regression analyses were performed.We included 168 patients: 79.2% women, mean age 54.5 years (±13.2 SD), mean disease duration 7.5 years (±7.3 SD). Mean number of prior DMARD: 1.4 (±1.2 SD), mean number of prior BT was 0.8 (±1.1). Mean time on CZP was 9.8 months (±3.4 SD). A total of 71.4% were receiving CZP at 12-month assessment. Baseline predictors of response: lower prior number DMARD; low number prior BT; higher CRP, ESR, TJC, SJC, DAS28 and SDAI (p 0.05) scores. A 25/46.4% Moderate/Good Response, a 20% SDAI remission, and a 44% DAS28 remission were observed. We observed 48 discontinuations (28.6%), 31 due to partial or complete ineffectiveness, and 17 due to side-effects.CZP showed benefit in severe RA patients, with significant reduction of all effectiveness parameters, despite the high prevalence of previous BT exposure in our series. We found CRP, ESR, prior DMARD/BT number, TJC, SJC, DAS28, and SDAI as baseline predictors of response. CZP was mostly well tolerated.
- Published
- 2016
4. Tocilizumab in refractory aortitis: study on 16 patients and literature review
- Author
-
Javier, Loricera, Ricardo, Blanco, Santos, Castañeda, Alicia, Humbría, Norberto, Ortego-Centeno, Javier, Narváez, Cristina, Mata, Sheila, Melchor, Elena, Aurrecoechea, Jaime, Calvo-Alén, Pau, Lluch, Concepción, Moll, Mauricio, Mínguez, Gabriel, Herrero-Beaumont, Beatriz, Bravo, Esteban, Rubio, Mercedes, Freire, Enriqueta, Peiró, Carmen, González-Vela, Javier, Rueda-Gotor, Trinitario, Pina, Natalia, Palmou-Fontana, Vanesa, Calvo-Río, Francisco, Ortiz-Sanjuán, and Miguel Ángel, González-Gay
- Subjects
Adult ,Male ,Aortitis ,Interleukin-6 ,Remission Induction ,Drug Resistance ,Middle Aged ,Antibodies, Monoclonal, Humanized ,Receptors, Interleukin-6 ,Spain ,Positron-Emission Tomography ,Outcome Assessment, Health Care ,Humans ,Prednisone ,Female ,Drug Monitoring ,Glucocorticoids ,Immunosuppressive Agents ,Magnetic Resonance Angiography ,Aged - Abstract
Non-infectious aortitis is often refractory to standard immunosuppressive therapy. Since IL-6 has been implicated in the pathogenesis of aortitis, we assessed the efficacy of the anti-IL6 receptor monoconal antibody tocilizumab (TCZ) in a series of patients with refractory non-infectious aortitis.Review of 16 patients (14 women/2 men) with refractory aortitis diagnosed by imaging (CT angiography, MR angiography, and/or PET) that were treated with TCZ.The mean age±SD was 51.4±20.1 years. The underlying conditions were: Takayasu arteritis (TakA) (n=7 cases), giant cell arteritis (GCA) (n=7), relapsing polychondritis (RP) (n=1), and aortitis associated with retroperitoneal fibrosis (n=1). TCZ was the first biologic drug used in all patients with GCA and in the patient with aortitis associated with retroperitoneal fibrosis but in only 2 of 7 TakA patients. In the remaining cases anti-TNF inhibitors were prescribed before TCZ (standard dose was 8 mg/kg/iv/4 weeks). After a mean±SD follow-up of 11.8±6.6 months most patients experienced clinical improvement, showing reduction of erythrocyte sedimentation rate from 43±36 mm/1st h to 5±4 mm/1st h at last visit. At TCZ onset, 25% of patients had fever and 19% polymyalgia rheumatica. These manifestations disappeared after 3 months of TCZ therapy. A corticosteroid sparing effect was also achieved (from 27.3±17.6 mg/day of prednisone at TCZ onset to 4.2±3.8 mg/day at last visit). TCZ had to be discontinued in a patient because of severe neutropenia.TCZ appears to be effective and relatively safe in patients with inflammatory aortitis refractory to corticosteroids or to other biologic immunosuppressive drugs.
- Published
- 2013
5. RENACER study: Assessment of 12-month efficacy and safety of 168 certolizumab PEGol rheumatoid arthritis-treated patients from a Spanish multicenter national database
- Author
-
V Torrente-Segarra, Vicenç Torrente-Segarra, A Urruticoechea Arana, Ana Urruticoechea Arana, A Sánchez-Andrade, Amalia Sánchez-Andrade Fernández, JV Tovar, Juan Víctor Tovar Beltrán, A Muñoz, Alejandro Muñoz Jiménez, A Martínez, Anna Martínez-Cristóbal, JA González, José Antonio González Ferrández, Manuel Fernández Prada, M Fernández, N. Vázquez, Noelia Vázquez Fuentes, Hèctor Corominas, H Corominas, Sílvia García-Díaz, S García-Díaz, A Acosta-Pereira, Asunción Acosta Pereira, José Miguel Ruiz Martín, JM Ruiz Martín, JR Lamua Riazuelo, José Ramón Lamua Riazuelo, Rosa Expósito Moliner, R Expósito, Desireé Ruiz Vilchez, D Ruiz Vilchez, R Veiga Cabello, Raúl Veiga Cabello, J Carlos Fernández, Jesús Carlos Fernández, José Raúl Noguera Pons, JR Noguera Pons, N Patricia Garrido Puñal, Noemí Patricia Garrido Puñal, Pedro Giralt Celiméndiz, P Giralt Celiméndiz, Raúl Cortés Verdú, R Cortés Verdú, Angel Aragón Díez, A Aragón Díez, Carlos Tomás Roura, C Tomás Roura, C Moll Turudi, Concepción Moll Turudi, Delia Taverner Torrent, D Taverner Torrent, Felipe Joaquín Rivas Santirso, FJ Rivas Santirso, Juan José Lerma Garrido, JJ Lerma Garrido, R García Portales, Rosa García Portales, Sergi Ordoñez Palau, S Ordoñez Palau, S Paredes González-Albo, Silvia Paredes González-Albo, A Gracia Pérez, Antonio Gracia Pérez, A Conesa Mateos, Arantxa Conesa Mateos, Jaime Calvo Alén, J Calvo Alén, Jenaro Graña Gil, J Graña Gil, María Pilar Navarro Alonso, MP Navarro Alonso, MJ Martínez Blasco, María Jesús Martínez Blasco, V Torrente-Segarra, Vicenç Torrente-Segarra, A Urruticoechea Arana, Ana Urruticoechea Arana, A Sánchez-Andrade, Amalia Sánchez-Andrade Fernández, JV Tovar, Juan Víctor Tovar Beltrán, A Muñoz, Alejandro Muñoz Jiménez, A Martínez, Anna Martínez-Cristóbal, JA González, José Antonio González Ferrández, Manuel Fernández Prada, M Fernández, N. Vázquez, Noelia Vázquez Fuentes, Hèctor Corominas, H Corominas, Sílvia García-Díaz, S García-Díaz, A Acosta-Pereira, Asunción Acosta Pereira, José Miguel Ruiz Martín, JM Ruiz Martín, JR Lamua Riazuelo, José Ramón Lamua Riazuelo, Rosa Expósito Moliner, R Expósito, Desireé Ruiz Vilchez, D Ruiz Vilchez, R Veiga Cabello, Raúl Veiga Cabello, J Carlos Fernández, Jesús Carlos Fernández, José Raúl Noguera Pons, JR Noguera Pons, N Patricia Garrido Puñal, Noemí Patricia Garrido Puñal, Pedro Giralt Celiméndiz, P Giralt Celiméndiz, Raúl Cortés Verdú, R Cortés Verdú, Angel Aragón Díez, A Aragón Díez, Carlos Tomás Roura, C Tomás Roura, C Moll Turudi, Concepción Moll Turudi, Delia Taverner Torrent, D Taverner Torrent, Felipe Joaquín Rivas Santirso, FJ Rivas Santirso, Juan José Lerma Garrido, JJ Lerma Garrido, R García Portales, Rosa García Portales, Sergi Ordoñez Palau, S Ordoñez Palau, S Paredes González-Albo, Silvia Paredes González-Albo, A Gracia Pérez, Antonio Gracia Pérez, A Conesa Mateos, Arantxa Conesa Mateos, Jaime Calvo Alén, J Calvo Alén, Jenaro Graña Gil, J Graña Gil, María Pilar Navarro Alonso, MP Navarro Alonso, MJ Martínez Blasco, and María Jesús Martínez Blasco
- Abstract
Objective: To assess effectiveness and safety of certolizumab PEGol (CZP) in rheumatoid arthritis (RA) patients after 12 months of treatment and to detect predictors of response.Methods: Observational longitudinal prospective study of RA patients from 35 sites in Spain. Variables (baseline, 3- and 12-month assessment): sociodemographics, previous Disease Modifying Anti-Rheumatic Drug (DMARD) and previous Biological Therapies (BT) use; TJC, SJC, ESR, CRP, DAS28, SDAI. Response variables: TJC, SJC, CRP, ESR, and steroids dose reductions, EULAR Moderate/Good Response, SDAI response and remission, DAS28 remission. Safety variables: discontinuation due to side-effects. Descriptive, comparative and Logistic regression analyses were performed.Results: We included 168 patients: 79.2% women, mean age 54.5 years (±13.2 SD), mean disease duration 7.5 years (±7.3 SD). Mean number of prior DMARD: 1.4 (±1.2 SD), mean number of prior BT was 0.8 (±1.1). Mean time on CZP was 9.8 months (±3.4 SD). A total of 71.4% were receiving CZP at 12-month assessment. Baseline predictors of response: lower prior number DMARD; low number prior BT; higher CRP, ESR, TJC, SJC, DAS28 and SDAI (p < 0.05) scores. A 25/46.4% Moderate/Good Response, a 20% SDAI remission, and a 44% DAS28 remission were observed. We observed 48 discontinuations (28.6%), 31 due to partial or complete ineffectiveness, and 17 due to side-effects.Conclusions: CZP showed benefit in severe RA patients, with significant reduction of all effectiveness parameters, despite the high prevalence of previous BT exposure in our series. We found CRP, ESR, prior DMARD/BT number, TJC, SJC, DAS28, and SDAI as baseline predictors of response. CZP was mostly well tolerated.
- Published
- 2015
- Full Text
- View/download PDF
6. RENACER study: Assessment of 12-month efficacy and safety of 168 certolizumab PEGol rheumatoid arthritis-treated patients from a Spanish multicenter national database
- Author
-
Vicenç Torrente-Segarra, Ana Urruticoechea Arana, Amalia Sánchez-Andrade Fernández, Juan Víctor Tovar Beltrán, Alejandro Muñoz Jiménez, Anna Martínez-Cristóbal, José Antonio González Ferrández, Manuel Fernández Prada, Noelia Vázquez Fuentes, Hèctor Corominas, Sílvia García-Díaz, Asunción Acosta Pereira, José Miguel Ruiz Martín, José Ramón Lamua Riazuelo, Rosa Expósito Moliner, Desireé Ruiz Vilchez, Raúl Veiga Cabello, Jesús Carlos Fernández, José Raúl Noguera Pons, Noemí Patricia Garrido Puñal, Pedro Giralt Celiméndiz, Raúl Cortés Verdú, Angel Aragón Díez, Carlos Tomás Roura, Concepción Moll Turudi, Delia Taverner Torrent, Felipe Joaquín Rivas Santirso, Juan José Lerma Garrido, Rosa García Portales, Sergi Ordoñez Palau, Silvia Paredes González-Albo, Antonio Gracia Pérez, Arantxa Conesa Mateos, Jaime Calvo Alén, Jenaro Graña Gil, María Pilar Navarro Alonso, María Jesús Martínez Blasco, Vicenç Torrente-Segarra, Ana Urruticoechea Arana, Amalia Sánchez-Andrade Fernández, Juan Víctor Tovar Beltrán, Alejandro Muñoz Jiménez, Anna Martínez-Cristóbal, José Antonio González Ferrández, Manuel Fernández Prada, Noelia Vázquez Fuentes, Hèctor Corominas, Sílvia García-Díaz, Asunción Acosta Pereira, José Miguel Ruiz Martín, José Ramón Lamua Riazuelo, Rosa Expósito Moliner, Desireé Ruiz Vilchez, Raúl Veiga Cabello, Jesús Carlos Fernández, José Raúl Noguera Pons, Noemí Patricia Garrido Puñal, Pedro Giralt Celiméndiz, Raúl Cortés Verdú, Angel Aragón Díez, Carlos Tomás Roura, Concepción Moll Turudi, Delia Taverner Torrent, Felipe Joaquín Rivas Santirso, Juan José Lerma Garrido, Rosa García Portales, Sergi Ordoñez Palau, Silvia Paredes González-Albo, Antonio Gracia Pérez, Arantxa Conesa Mateos, Jaime Calvo Alén, Jenaro Graña Gil, María Pilar Navarro Alonso, and María Jesús Martínez Blasco
- Published
- 2015
- Full Text
- View/download PDF
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.